Emsley 1995.

Methods	Allocation: randomised (no further description). Blindness: double (no further description). Duration: 6 weeks. Consent: not stated. Setting: multicentre, multinational.
Participants	Diagnosis:schizophrenia or schizophreniform disorder (DSM‐III‐R). N=183. Sex: 122M, 61F. Age: 15‐50 years. History: first‐episode. Exclusions: not stated
Interventions	1. Risperidone: 2‐16 mg/day, an initial dose of 4mg/day was adjusted as required throughout the trial. N=99. 2. Haloperidol: 1‐16 mg/day, an initial dose of 4mg/day was adjusted as required throughout the trial. N=84.
Outcomes	Clinical improvement: >50% in PANSS. Adverse effects: various observed effects. Leaving the study early. Unable to use ‐ Global effect: CGI score (no SD). Mental state BPRS ‐ PANSS derived, PANSS (no SD). Physiological monitoring: ECG, lab tests (no data) Adverse effects: ESRS (no SD).
Notes
Risk of bias
Bias	Authors' judgement	Support for judgement
Allocation concealment?	Unclear risk	B ‐ Unclear